Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CHKA | P35790 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | CASP7 | P55210 | 1/20 | 0.37 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12490959 | 0.90 | HTR2A (0.41) | ALDH1A1MEN1KMT2AACHECHKA | |
| SCHEMBL12682909 | 0.87 | ALDH1A1 (0.54) | ALDH1A1MEN1KMT2AACHEGAA | |
| SCHEMBL763146 | 0.85 | ALDH1A1 (0.44) | ALDH1A1MEN1KMT2AACHEGAA | |
| SCHEMBL24937850 | 0.81 | ALDH1A1 (0.41) | ALDH1A1MEN1KMT2AACHEGAA | |
| SCHEMBL19601657 | 0.81 | RORC (0.44) | ALDH1A1MEN1KMT2AACHEGAA | |
| SCHEMBL554421 | 0.78 | KLKB1 (0.45) | ALDH1A1MEN1KMT2AGAAMAPT | |
| SCHEMBL1282891 | 0.77 | DRD1 (0.53) | ALDH1A1MEN1KMT2AACHEGAA | |
| SCHEMBL6211902 | 0.76 | CHRM2 (0.49) | ALDH1A1MEN1KMT2AACHEGAA | |
| SCHEMBL2616323 | 0.75 | ALDH1A1 (0.60) | ALDH1A1MEN1KMT2AACHEGAA | |
| SCHEMBL3501876 | 0.75 | ACHE (0.48) | ACHEMAPTTYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2683710-B1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | BOEHRINGER INGELHEIM INT (DE) | 2017-07-19 | — | — | EP | disclosed |
| EP-2683710-B1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | BOEHRINGER INGELHEIM INT (DE) | 2017-07-19 | — | — | EP | disclosed |
| US-9695166-B2 | Pyrazolopyridine pyrazolopyrimidine and related compounds | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-9695166-B2 | Pyrazolopyridine pyrazolopyrimidine and related compounds | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-9695166-B2 | Pyrazolopyridine pyrazolopyrimidine and related compounds | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-9290485-B2 | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides | NOVARTIS AG (CH) | 2016-03-22 | — | — | US | disclosed |
| US-9290485-B2 | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides | NOVARTIS AG (CH) | 2016-03-22 | — | — | US | disclosed |
| US-9290485-B2 | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides | NOVARTIS AG (CH) | 2016-03-22 | — | — | US | disclosed |
| WO-2015171527-A1 | PYRAZOLOPYRIDINE PYRAZOLOPYRIMIDINE AND RELATED COMPOUNDS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2015-11-12 | — | — | WO | disclosed |
| WO-2015171527-A1 | PYRAZOLOPYRIDINE PYRAZOLOPYRIMIDINE AND RELATED COMPOUNDS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2015-11-12 | — | — | WO | disclosed |
| US-20130065918-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-03-14 | — | — | US | disclosed |
| US-20130065918-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-03-14 | — | — | US | disclosed |
| US-20130065918-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-03-14 | — | — | US | disclosed |
| WO-2012122340-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-13 | — | — | WO | disclosed |
| WO-2012122340-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-13 | — | — | WO | disclosed |
| US-20120035168-A1 | N-((6-AMINO-PYRIDIN-3-YL)METHYL)-HETEROARYL-CARBOXAMIDES | NOVARTIS AG (CH) | 2012-02-09 | — | — | US | disclosed |
| US-20120035168-A1 | N-((6-AMINO-PYRIDIN-3-YL)METHYL)-HETEROARYL-CARBOXAMIDES | NOVARTIS AG (CH) | 2012-02-09 | — | — | US | disclosed |
| US-20120035168-A1 | N-((6-AMINO-PYRIDIN-3-YL)METHYL)-HETEROARYL-CARBOXAMIDES | NOVARTIS AG (CH) | 2012-02-09 | — | — | US | disclosed |
| WO-2012017020-A1 | N-((6-AMINO-PYRIDIN-3-YL)METHYL)-HETEROARYL-CARBOXAMIDES AS INHIBITORS OF PLASMA KALLIKREIN | NOVARTIS AG (CH) | 2012-02-09 | — | — | WO | disclosed |
| WO-2012017020-A1 | N-((6-AMINO-PYRIDIN-3-YL)METHYL)-HETEROARYL-CARBOXAMIDES AS INHIBITORS OF PLASMA KALLIKREIN | NOVARTIS AG (CH) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065918-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | GUCY1A1, GUCY1A2, GUCY1B1 | ALDH1A1 1104/4885MEN1 843/4885KMT2A 4392/4885 |
| US-20120035168-A1 | N-((6-AMINO-PYRIDIN-3-YL)METHYL)-HETEROARYL-CARBOXAMIDES | TPMT, REN, PNMT | ALDH1A1 1337/4885MEN1 612/4885KMT2A 323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.